Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects
Status:
Recruiting
Trial end date:
2023-06-17
Target enrollment:
Participant gender:
Summary
This study will evaluate SYNB1891 (investigational product) administered as intratumoral
injections in subjects diagnosed with advanced/metastatic solid tumors and lymphoma for
possible treatment. Eligible subjects will receive SYNB1891 intratumorally and will undergo
imaging to assess tumor response, safety monitoring and subsequent follow-up after
investigational product (IP) administration. Once dose limiting toxicity (DLT) for SYNB1891
is determined, it will be administered at one log dose level lower in combination with
atezolizumab.